Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Aug. 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V.  (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics ® , Triclonics ®  and